UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 230

Sortiert nach

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma

Annals of oncology, 2012-02, Vol.23 (2), p.406-410

2012

Volltextzugriff (PDF)

A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma

European journal of cancer (1990), 2014-04, Vol.50 (6), p.1084-1089

2014

Volltextzugriff (PDF)

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib

Annals of oncology, 2008-02, Vol.19 (2), p.265-268

2008

Volltextzugriff (PDF)

A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer

Prostate cancer and prostatic diseases, 2015-09, Vol.18 (3), p.242-248

2015

Volltextzugriff (PDF)

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet

Annals of oncology, 2018-01, Vol.29 (1), p.23-25

2018

Volltextzugriff (PDF)

2526 Immune responses and clinical data from STRIDE, a randomized, phase 2, open label study of sipuleucel-T with concurrent vs sequential enzalutamide administration in metastatic castrationresistant prostate cancer

European journal of cancer (1990), 2015-09, Vol.51, p.S483-S483

2015

Volltextzugriff (PDF)

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

Investigational new drugs, 2009-08, Vol.27 (4), p.379-386

2009

Volltextzugriff (PDF)

Phase II Trial of Neoadjuvant Nab-Paclitaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

The Journal of urology, 2009-04, Vol.181 (4), p.1672-1677

2009

Volltextzugriff (PDF)

Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder Preserving Combined Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of RTOG 9906 and 0233

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.S132-S132

2014

Volltextzugriff (PDF)

21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)

European journal of cancer (1990), 2015-09, Vol.51, p.S720-S720

2015

Volltextzugriff (PDF)

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

Journal of clinical oncology, 1997-02, Vol.15 (2), p.589-593

1997

Volltextzugriff (PDF)

7014 POSTER DISCUSSION Evaluation of Circulating Tumour Cells (CTCs) in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Receiving TAK-700, an Investigational 17,20-lyase Inhibitor

European journal of cancer (1990), 2011, Vol.47, p.S488-S488

2011

Volltextzugriff (PDF)

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

Journal of clinical oncology, 1994-11, Vol.12 (11), p.2264-2270

1994

Volltextzugriff (PDF)

1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations

Annals of oncology, 2023-10, Vol.34, p.S973-S974

2023

Volltextzugriff (PDF)

Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease

Investigational new drugs, 2008-12, Vol.26 (6), p.553

2008

Volltextzugriff (PDF)

Locally advanced and metastatic bladder cancer

Current treatment options in oncology, 2001-10, Vol.2 (5), p.431-436

Dreicer, R

2001

Volltextzugriff (PDF)

Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?

European journal of cancer (1990), 2005-04, Vol.41 (6), p.954-964

2005

Volltextzugriff (PDF)

2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)

Annals of oncology, 2023-10, Vol.34, p.S1203-S1203

2023

Volltextzugriff (PDF)

651O Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)

Annals of oncology, 2021-09, Vol.32, p.S678-S678

2021

Volltextzugriff (PDF)

LBA24 Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study

Annals of oncology, 2021-09, Vol.32, p.S1299-S1300

2021

Volltextzugriff (PDF)

Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial

Annals of oncology, 2016-10, Vol.27, p.vi244-vi244

2016

Volltextzugriff (PDF)

Paclitaxel in Advanced Urothelial Carcinoma: Its Role in Patients with Renal Insufficiency and as Salvage Therapy

The Journal of urology, 1996-11, Vol.156 (5), p.1606-1608

1996

Volltextzugriff (PDF)

Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors

Investigational new drugs, 2007-06, Vol.25 (3), p.211-216

2007

Volltextzugriff (PDF)

845PD - CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors

Annals of oncology, 2019-10, Vol.30, p.v326-v327

2019

Volltextzugriff (PDF)

CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors

Annals of oncology, 2019-10, Vol.30, p.v326-v327

2019

Volltextzugriff (PDF)

1 – 25 von 230

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(214)
Mit Volltextzugriff
(202)

Publikationsform

Sprache

Englisch
(230)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Humans
(109)
Science & Technology
(106)
Life Sciences & Biomedicine
(100)
Male
(92)
Middle Aged
(68)
Oncology
(68)
Aged
(65)
Biological And Medical Sciences
(53)
Medical Sciences
(53)
Female
(46)
Adult
(35)
Chemotherapy
(35)
Pharmacology. Drug Treatments
(34)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(33)
Antineoplastic Agents
(32)
Treatment Outcome
(32)
Urology & Nephrology
(26)
Aged, 80 And Over
(24)
Prostatic Neoplasms - Drug Therapy
(21)
Tumors
(21)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma

A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib

A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet

2526 Immune responses and clinical data from STRIDE, a randomized, phase 2, open label study of sipuleucel-T with concurrent vs sequential enzalutamide administration in metastatic castrationresistant prostate cancer

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

Phase II Trial of Neoadjuvant Nab-Paclitaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder Preserving Combined Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of RTOG 9906 and 0233

21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

7014 POSTER DISCUSSION Evaluation of Circulating Tumour Cells (CTCs) in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Receiving TAK-700, an Investigational 17,20-lyase Inhibitor

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations

Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease

Locally advanced and metastatic bladder cancer

Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?

2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)

651O Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)

LBA24 Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study

Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial

Paclitaxel in Advanced Urothelial Carcinoma: Its Role in Patients with Renal Insufficiency and as Salvage Therapy

Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors

845PD - CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors

CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors

Suchergebnisse filtern